Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADA
REST API REST API
Homo sapiens
ADA is differentially expressed in 344 experiments: 113 organism parts: thymus, kidney, ... (111 more);, 218 disease states: normal, control, ... (216 more);, 110 cell types 439 cell lines 51 compound treatments and 81 other conditions.
Orthologs AAH1 (Saccharomyces cerevisiae)   F6WSV9_CIOIN (Ciona intestinalis)   ada (Danio rerio)   A6H7A2_BOVIN (Bos taurus)   Ada (Mus musculus)   F1P2A6_CHICK (Gallus gallus)   Ada (Rattus norvegicus)   ada.2 (Xenopus laevis)   ada (Xenopus laevis)   Q9XT63_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, response to hydrogen peroxide, plasma membrane, protein binding, cytoplasm, extracellular space, embryonic digestive tract development, membrane, lysosome, negative regulation of apoptosis, metal ion binding, nucleotide metabolic process, response to hypoxia, cell junction, external side of plasma membrane, cell adhesion, purine ribonucleoside monophosphate biosynthetic process, aging, deaminase activity, cytoplasmic vesicle, hydrolase activity, adenosine deaminase activity, cell surface, regulation of circadian sleep/wake cycle, sleep, purine base metabolic process, zinc ion binding, neuronal cell body, xanthine biosynthetic process, positive regulation of T cell activation, purine nucleoside binding, hypoxanthine biosynthetic process, positive regulation of B cell proliferation, Peyer's patch development, positive regulation of heart rate, positive regulation of smooth muscle contraction, adenosine metabolic process, regulation of T cell differentiation, in utero embryonic development, negative regulation of thymocyte apoptosis, positive regulation of germinal center formation, regulation of cell-cell adhesion mediated by integrin, response to morphine, deoxyadenosine catabolic process, T cell activation, placenta development, positive regulation of alpha-beta T cell differentiation, negative regulation of inflammatory response, lung alveolus development, negative regulation of adenosine receptor signaling pathway, negative regulation of leukocyte migration, negative regulation of mature B cell apoptosis, negative regulation of penile erection, purine nucleotide salvage, positive regulation of calcium-mediated signaling, histamine secretion, germinal center B cell differentiation, lung development, positive regulation of T cell differentiation, dATP catabolic process, liver development, inosine biosynthetic process, adenosine catabolic process, negative regulation of mucus secretion, trophectodermal cell differentiation, dendrite cytoplasm, positive regulation of T cell receptor signaling pathway, hypoxanthine salvage, positive regulation of T cell differentiation in thymus, purine-containing compound salvage, cytoplasmic membrane-bounded vesicle lumen, negative regulation of circadian sleep/wake cycle, non-REM sleep, nucleobase-containing small molecule metabolic process
InterPro Term A/AMP_deaminase, A_deaminase
UniProt Accession P00813, F5GWI4, F5GXW0, F5GYD4
Gene-Disease Assocation SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,
Search EB-eye ENSG00000196839
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (46 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529, E-GEOD-19639
HL-60
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
Jurkat
3
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-5823, E-GEOD-3529
433 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-MEXP-750, E-GEOD-20677, ... (52 experiments)

Factor Value U/D Experiments
CD4+ T cell
3
E-MEXP-1600, E-GEOD-16190, E-GEOD-6740
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
stromal cell
1
2
E-GEOD-1460, E-MEXP-1327, E-GEOD-10797
endothelial cells and pericytes
1
E-MEXP-1251
activated natural killer cell
1
E-TABM-702
monocyte-derived intermediate cell
1
E-MEXP-2019
104 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2280, E-GEOD-16363, E-GEOD-20168, ... (68 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-GEOD-96, E-MEXP-2034, E-MEXP-1327, E-MTAB-62
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
head and neck squamous cell carcinoma
2
E-GEOD-6631, E-GEOD-2379
lung adenocarcinoma
2
E-MTAB-62, E-MEXP-231
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
212 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-GEOD-5741, E-TABM-782, ... (32 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
hydroxyurea
1
E-GEOD-6431
CNOT7 + non-targeting
1
E-MEXP-2218
N-nitrosodimethylamine
1
E-GEOD-6907
ponasterone A
1
E-GEOD-3113
saline
1
E-GEOD-3026
45 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, ... (11 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-2509, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-TABM-868, E-GEOD-18005, E-TABM-601, E-MEXP-1838, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-10433, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-MEXP-1412, E-GEOD-1460, ... (7 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.326 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM